Regarding novelty, to the best of our knowledge, our trial is the first to describe that adiponectin and resistin levels may increase as a result of MM treatment and that adipsin is a potential biomarker of disease activity, while TSP-1 levels in peripheral blood are significantly elevated compared to healthy controls. The gene discussed is THBS1; the disease is Miyoshi myopathy.